Austin Journal of Multiple Sclerosis and Neuroimmunology
Current Therapies for Multiple Sclerosis: A Brief Review
Recent scientific advances have led to improved therapies for multiple sclerosis (MS). Current therapies are aimed at decreasing the damage incurred by neurons as well as attempting to restore proper function. However, all of the Food and Drug Administration (FDA) approved therapies are only indicated for treatment of relapsing remitting and/or relapsing forms of MS as they specifically target immune components, which play a main role in relapses. These drugs can reduce relapse rate and severity of relapses, as well as inhibit disease progression. This review will focus on the current and recently approved therapies for relapsing remitting MS, exploring how the main drugs target specific aspects of MS pathology so as to ameliorate disease.
Read full article